Neuroscientific Biopharmaceuticals

This company’s lead candidate is EmtinB, a therapeutic peptide with initial applications in Alzheimer’s disease and glaucoma. EmtinB is modelled on a key protein produced by the body’s innate immune system in response to injury. The pre-clinical data on EmtinB has so far looked very positive – the drug slowed cognitive decline in an animal model of Alzheimer’s – and the early clinical studies are now being prepared. A Phase 1 ocular study will kick off late in 2021.
Read the most recent article...

Save $$$
30-Day Free Trial
$0
No Credit Card Required!
Get access to 4 publications
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
Profit Premium
$69
Get access to 4 publications
Access to the full research Archive
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
30-Day Free Trial
$0
No Credit Card Required!
Get access to 4 publications
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
Profit Premium
$59
BILLED ANNUALLY
Get access to 4 publications
Access to the full research Archive
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks